Since the MOA agents listed for SOM meta-clades 21 through 24 have roles in DNA damage, defective CDKN2A, RPTOR and KRAS may contribute to chemosensitivity of tumor cell lines to these agents. This evidence concerns the gene KRAS and neoplasm.